Adverse drug reactions following treatment of latent tuberculosis infection: a linked national tuberculosis surveillance with claims database
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Few real-world studies explored factors associated with latent tuberculosis infection (LTBI) treatment-related adverse drug reactions (ADRs). This study evaluate ADRs that lead to the discontinuation of LTBI treatment and identify the associated factors, including age groups and drug regimens. Methods: Using the Korean national tuberculosis registry and HHC investigation database linked to the National Health Insurance Service claims database, we examined treatment discontinuation due to ADRs among HHCs on LTBI treatment from January 2015 to December 2018. Multivariable logistic regression analysis was conducted to examine factors associated with ADRs, including demographics, LTBI treatment, comorbidities, and steroid use. Results: Among 11,913 participants initiated LTBI treatment, 633 participants (5.3%) discontinued treatment due to ADRs. The primary contributors to discontinuation were adverse skin reactions (2.0%) and abnormal liver function (1.9%). Risk associated with ADRs and abnormal liver function showed age-related increase, except for the age group 66–75 (adjusted odds ratio [AOR] 3.82, 95% confidence interval [CI] 2.31–6.31) which reported lower OR to that of age group 36–65 (AOR 4.38, 95% CI 3.09–6.21). Three months isoniazid/rifampin and 4 months rifampin exhibited a lower odds of ADRs and abnormal liver function when compared to 6–9 months isoniazid. Conclusions: We discovered the real-world prevalence of LTBI treatment discontinuation due to ADRs among HHCs. Our findings suggest a notably increased odds of ADRs resulting in discontinuation with age of 76 years or above, emphasizing careful attention when prescribing LTBI treatment in this population. Further studies are warranted to validate these results.
Abstract
Background/Aims: Few real-world studies explored factors associated with latent tuberculosis infection (LTBI) treatment-related adverse drug reactions (ADRs). This study evaluate ADRs that lead to the discontinuation of LTBI treatment and identify the associated factors, including age groups and drug regimens. Methods: Using the Korean national tuberculosis registry and HHC investigation database linked to the National Health Insurance Service claims database, we examined treatment discontinuation due to ADRs among HHCs on LTBI treatment from January 2015 to December 2018. Multivariable logistic regression analysis was conducted to examine factors associated with ADRs, including demographics, LTBI treatment, comorbidities, and steroid use. Results: Among 11,913 participants initiated LTBI treatment, 633 participants (5.3%) discontinued treatment due to ADRs. The primary contributors to discontinuation were adverse skin reactions (2.0%) and abnormal liver function (1.9%). Risk associated with ADRs and abnormal liver function showed age-related increase, except for the age group 66–75 (adjusted odds ratio [AOR] 3.82, 95% confidence interval [CI] 2.31–6.31) which reported lower OR to that of age group 36–65 (AOR 4.38, 95% CI 3.09–6.21). Three months isoniazid/rifampin and 4 months rifampin exhibited a lower odds of ADRs and abnormal liver function when compared to 6–9 months isoniazid. Conclusions: We discovered the real-world prevalence of LTBI treatment discontinuation due to ADRs among HHCs. Our findings suggest a notably increased odds of ADRs resulting in discontinuation with age of 76 years or above, emphasizing careful attention when prescribing LTBI treatment in this population. Further studies are warranted to validate these results.
참고문헌 (20)
- Cohen A, "The global prevalence of latent tuberculosis : a systematic review and metaanalysis", Eur Respir J, 54, pp.1900655~ (2019)
- Comstock GW, "The prognosis of a positive tuberculin reaction in childhood and adolescence", Am J Epidemiol, 99, pp.131~138 (1974)
- Vynnycky E, "The natural history of tuberculosis : the implications of age-dependent risks of disease and the role of reinfection", Epidemiol Infect, 119, pp.183~201 (1997)
- "Guidelines on the management of latent tuberculosis infection" (2015)[URL]
- Jeon D, "Latent tuberculosis infection : recent progress and challenges in South Korea", Korean J Intern Med, 35, pp.269~275 (2020)
- Go U, "Tuberculosis prevention and care in Korea : Evolution of policy and practice", J Clin Tuberc Other Mycobact Dis, 11, pp.28~36 (2018)
- "National guideline on management of tuberculosis 2023" (2023)[URL]
- Yang J, "The risk of active tuberculosis among individuals living in tuberculosis-affected households in the Republic of Korea, 2015", PLoS One, 14, pp.e0225744~ (2019)
- Yang H, "Factors influencing the initiation and adherence of LTBI treatment in healthcare workers : a systematic review", Arch Environ Occup Health, 77, pp.76~86 (2022)
- Joint Committee for the Revision of Korean Guidelines for Tuberculosis Korea Centers for Disease Control and Prevention, "Korean guidlines for tuberculosis" (2020), Korea Disease Control and Prevention Agency
- Seong SC, "Data resource profile : the National Health Information Database of the National Health Insurance Service in South Korea", Int J Epidemiol, 46, pp.799~800 (2017)
- Quan H, "Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data", Med Care, 43, pp.1130~1139 (2005)
- Campbell JR, "Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid : post-hoc safety analysis of two randomised controlled trials", Lancet Infect Dis, 20, pp.318~329 (2020)
- Schein YL, "Treatment completion for latent tuberculosis infection in Norway : a prospective cohort study", BMC Infect Dis, 18, pp.587~ (2018)
- Castro AT, "Incidence and risk factors of major toxicity associated to first-line antituberculosis drugs for latent and active tuberculosis during a period of 10years", Rev Port Pneumol(2006), 21, pp.144~150 (2015)
- Lee H, "Characteristics of Notified Tuberculosis Cases — Republic of Korea, 2022", Public Health Weekly Report, 16, pp.931~949 (2023)
- Feng JY, "Safety and treatment completion of latent tuberculosis infection treatment in the elderly population-a prospective observational study in Taiwan", Int J Infect Dis, 96, pp.550~557 (2020)
- Noh CS, "Completion rate of latent tuberculosis infection treatment in patients aged 65 years and older", Respir Med, 157, pp.52~58 (2019)
- Dorman SE, "Four-month rifapentine regimens with or without moxifloxacin for tuberculosis", N Engl J Med, 384, pp.1705~1718 (2021)
- Sterling TR, "Guidelines for the treatment of latent tuberculosis infection : recommendations from the National Tuberculosis Controllers Association and CDC, 2020", MMWR Recomm Rep, 69, pp.1~11 (2020)